Color Code
Light Blue

500 Cities Project

New Interactive Web Application

Learn More

To ensure the health of America’s neighborhoods and communities, it is vital to understand the scope of the nation's most pressing health challenges. The CDC Foundation is partnering with the Centers for Disease Control and Prevention (CDC) and the Robert Wood Johnson Foundation to release a first-of-its-kind data analysis for the 500 largest American cities, and the census tracts within cities, to identify, analyze and report data for a select number of chronic disease measures.

The 500 Cities Project will help inform the development and implementation of effective and targeted public health prevention activities in many of America’s cities. The CDC Foundation announced the launch of this project in February 2016.

new, interactive web application is also now available for users to view and explore city-and neighborhood-level health data for America’s 500 largest cities. The web application enables public health professionals, policymakers, and researchers to see and use the data to effectively address and target interventions to specific areas where they are most needed. The interactive mapping application enables users to zoom in to their neighborhood and look at local data compared with data for the entire city.  

This data will focus on conditions, behaviors and risk factors that have a substantial impact on public health.

Learn More 

500 Cities Data

Project Purpose and Unique Value

Frequently Asked Questions

List of 500 Cities

Meeting Materials

887
500 Cities
500 Cities Project
United States of America
To promote chronic disease prevention and health promotion for the 500 largest American cities by identifying, analyzing and reporting census tract-level data through an interactive City Health Indicator website.
Robert Wood Johnson Foundation
CDC's National Center for Chronic Disease Prevention and Health Promotion

Tackling Hunger to Improve Health in Americans

885
Food
Tackling Hunger to Improve Health in Americans
Ohio, USA
United States of America
To identify and disseminate effective strategies to address the cycle of food insecurity and its relationship to acute medical events in people with chronic diseases.
ProMedica; AARP Foundation
CDC's National Center for Chronic Disease Prevention and Health Promotion

Sickle Cell Data Collection (SCDC) Program

855
SCD
Sickle Cell Data Collection (SCDC) Program
Georgia and California, USA
United States of America
To build the framework for collecting data about individuals in the United States with sickle cell disease in order to monitor their health outcomes, evaluate current systems of care, and inform the development of a comprehensive care model to meet the needs of these individuals throughout their life.
Biogen; Pfizer Inc.; Global Blood Therapeutics
CDC’s National Center on Birth Defects and Developmental Disabilities

Screening of Congenital Adrenal Hyperplasia

814
chronic
Screening of Congenital Adrenal Hyperplasia
Minnesota, USA
United States of America
To determine the impact of molecular testing on newborn screening for Congenital Adrenal Hyperplasia (CAH). The goal of the project is to improve clinical outcomes by early detection and treatment of infants affected by CAH and to reduce the burden of false positives on families and providers.
University of Minnesota (National Institutes of Health)
CDC's Division of Laboratory Sciences

Healthy People 2020 Law and Health Policy Project

To develop progress reports linked to Healthy People 2020 (a science-based, 10-year national objective for improving the health of Americans) to demonstrate the value of legal and policy interventions in improving Americans' health.

751
chronic
Healthy People 2020 Law and Health Policy Project
United States of America
To develop progress reports linked to Healthy People 2020 (a science-based, 10-year national objective for improving the health of Americans) to demonstrate the value of legal and policy interventions in improving Americans' health.
Robert Wood Johnson Foundation
CDC's National Center for Chronic Disease Prevention and Health Promotion

Laboratory Surveillance for Factor XIII Deficiency

763
chronic
Laboratory Surveillance for Factor XIII Deficiency
United States of America
To provide support for Factor XIII testing to accurately diagnose patients in the United States in order to enhance the surveillance of rare bleeding disorders.
Novo Nordisk Inc.
CDC’s National Center on Birth Defects and Developmental Disabilities

Hormone Laboratory Collaborations

524
Lab
Hormone Laboratory Collaborations
United States of America
To help CDC provide reference and quality control materials for laboratory collaboration, including collaborations for the Hormone Measurement Standardization program.
AB SCIEX; Abbott Laboratories; American University of Beirut; Ann & Robert H. Lurie Children's Hospital of Chicago; ARUP Laboratories; Beckman Coulter, Inc.; Bio-Rad Laboratories, Inc.; BMH Holdings (TMS BioScience Labs); Covance; DiaSorin Inc.; DIAsource Immunoassays; Douglass Hanly Moir Pathology; Endoceutics, Inc.; Euroimmun Medizinische Labordiagnostika AG; Fujirebio Diagnostics, Inc; Fujirebio Inc.; Health Canada; Immunodiagnostic Systems Inc.; Immunotech S.A.S. (Beckman Coulter, Inc); Laboratory Corporation of America Holdings; Los Angeles Biomedical Research Institute; Microgenics Corporation (Thermo Fisher Scientific, Inc.); New England Research Institutes, Inc.; Harvard University (Partners HealthCare System, Inc.); Pathology Associates Medical Laboratories; Quest Diagnostics; Reprosource Fertility Diagnostics; Roche Diagnostics Corporation; Sahlgrenska University Hospital; Siemens; Social & Scientific Systems, Inc.; Tosoh Bioscience, Inc.; Tricore Reference Laboratories; University College Cork; University of Helsinki; VU University Medical Center Amsterdam; ZRT Laboratory; multiple donors
CDC's Division of Laboratory Sciences

Newborn Screening Translation Research Initiative

newborn screeningFor new parents the world over, the birth of a healthy child is a joy they remember throughout their lives. For some, however, that joy is tempered by serious health problems that arise from disorders like phenylketonuria, sickle cell disease or hypothyroidism. Fortunately for thousands of babies born in the United States each year, those treatable diseases are caught and diagnosed within days of birth, thanks in large part to the work of the newborn screening laboratory program at the Centers for Disease Control and Prevention.

“Newborn screening is the most successful lab-based prevention program in public health,” says Dr. Robert Vogt, principal investigator of the Newborn Screening Translation Research Initiative (NSTRI).

Virtually all babies born in the United States are tested for an array of treatable, but potentially deadly, conditions within 48 hours of birth. Blood samples collected by a simple “heel stick” are sent to one of more than 70 newborn screening labs across the country for analysis. Testing in these labs is routinely evaluated by CDC’s Newborn Screening and Molecular Biology Branch, which operates the only comprehensive program in the world for assuring the quality of newborn screening tests. The reach of the CDC program also extends to over 450 labs in more than 60 countries.

Currently, early detection by laboratory tests helps prevent death and disability from dozens of disorders. Early identification of these disorders gives babies a healthy start and dramatically reduces health care costs associated with treatment of lifelong debilitating conditions.

For the future, the CDC research group is working to identify new tests to add to the mix. Dr. Vogt boils down the research conducted by his program into a simple summary saying, “The purpose of this group is to anticipate screening tests that are not now being conducted.”

The CDC Program was instrumental in expanding the recommended panel of newborn screening tests to include Severe Combined Immune Deficiency (SCID), known more commonly as the Boy in the Bubble Syndrome. The screen is now being piloted at labs in Wisconsin and Massachusetts, and thus far more than 200,000 babies have been screened for the syndrome. The first newborn with SCID was identified just this year. The screening test should soon become routine throughout the United States, adding yet another layer of protection for newborns.

Gathered with his research colleagues near their lab at CDC, Dr. Vogt is quick to recognize the role of the CDC Foundation. “We now have five major areas of investigation that are supported in one way or another by the CDC Foundation,” he says. “In some cases it is direct funding support and in other cases there are partnerships that are in-kind. We use the CDC Foundation to ‘do more, faster.’ That motto really applies.”

by David Snyder

328/ 779
Newborn screening
Newborn Screening Translation Research Initiative
United States of America
To improve four major areas of newborn screening: 1) developing new screening methods for specific diseases, 2) integrating state public health laboratories in the translation process through collaborative field studies, 3) expanding the global reach of newborn screening, and 4) adapting innovative technologies for screening and quality assurance.
Genzyme Corporation; Biogen
CDC’s National Center for Environmental Health; California Department of Health Services; Emory University; Jeffrey Modell Foundation; Kennedy Krieger Institute; Medical College of Georgia; New York State Department of Health; The Johns Hopkins Bloomberg School of Public Health; The University of Texas at San Antonio; University of Washington; Washington State Department of Health; Wisconsin State Laboratory of Hygiene; Association of Public Health Laboratories; Illinois Department of Public Health; Georgia Public Health Laboratory; University of California San Francisco; New England Newborn Screening Program; University of Pittsburgh Medical Center Mayo Clinic; University of Pittsburgh School of Medicine; National Taiwan University Hospital
Subscribe to Chronic Disease & Birth Defects